South Florida Injury Lawyer Blog
Mounjaro, manufactured by Eli Lilly and Co., is an injectable prescription medicine that is used along with diet and exercise to improve blood sugar in adults with type 2 diabetes mellitus. Mounjaro received FDA approval in May of 2022.
Mounjaro is a glucagon-like peptide-1 (GLP-1) receptor agonist, like Ozempic, which is produced by Novo Nordisk. In addition, Mounjaro also activates glucose-dependent insulinotropic peptide (GIP), a hormone that helps release insulin after consumption.
Eli Lilly claims on the Mounjaro website that studies showed 3 out of 4 people reached an A1C under 7%, from an average starting at 7.9% to 8.6%.